Insertion of the DNA for the 163-171 peptide of IL1β enables a DNA vaccine encoding p185neu to inhibit mammary carcinogenesis in Her-2/neu transgenic BALB/c mice

Gene Therapy

Volumn 8, Issue 6, 2001, Pages 447-452

  Rovero, S ^a   Boggio, K ^a   Carlo, E Di ^b   Amici, A ^c   Quaglino, E ^a   Porcedda, P ^a   Musiani, P ^b   Forni, G ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c UNIVERSITY OF CAMERINO   (Italy)

Author keywords

DNA immunization; Her 2 neu; IL 1 ; Mammary carcinogenesis; Tumor prevention

Indexed keywords

DNA VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G2A; INTERLEUKIN 1BETA; NONAPEPTIDE; PLASMID DNA; PROTEIN P185;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY PRODUCTION; ARTICLE; BREAST ADENOCARCINOMA; BREAST CARCINOGENESIS; BREAST HYPERPLASIA; CANCER INVASION; CARCINOMA IN SITU; CELL INFILTRATION; CONTROLLED STUDY; CORRELATION FUNCTION; DRUG EFFICACY; FEMALE; GENE INSERTION; GENETIC CODE; IMMUNE RESPONSE; IMMUNOMODULATION; INFLAMMATION; LEUKOCYTE; MOUSE; MULTIPLE CANCER; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN DOMAIN; STROMA; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES; FEMALE; GENE THERAPY; GENES, ERBB-2; INTERLEUKIN-1; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; RATS; STATISTICS, NONPARAMETRIC; VACCINES, DNA;

MUS MUSCULUS;

EID: 0035065561     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301416     Document Type: Article

References (34)

1. Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment
2. Vaccination of seronegative volunteers with a human immunodeficiency virus type1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines
3. Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers
4. Genetic vaccination: The advantages of going naked
5. Accessories for naked DNA vaccination
6. Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction
7. Cytokine gene-engineered vaccines
8. Cytokines, tumor cell death and immunogenicity: A question of choice
9. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B cell lymphoma
10. The adjuvanticity of interleukin 1 in vivo
11. In vivo stimulation and restoration of the immune response by the noninflammatory fragment 163-171 of human interleukin 1β
12. Lymphokine-activated tumor inhibition in mice. Ability of a nonapeptide of human IL1β to recruit anti-tumor reactivity in recipient mice
13. Increasing the immunogenicity of protein antigens through the genetic insertion of VQGEESNDK sequence of human IL-1 beta into their sequence
14. Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy of IL-2, IL-4, and granulocyte-macrophage colony-stimulating factor
15. Interleukin-12 mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice
16. Analysis of mammary carcinoma onset and progression in Her-2/neu oncogene transgenic mice reveals a lobular origin
17. Genetic immunization against neu/erbB2 transgenic breast cancer
18. DNA vaccination with full-length or truncated Neu induces protective immunity against the development of spontaneous mammary tumors in HER-2/neu transgenic mice
19. DNA vaccination against rat Her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice
20. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies
21. Prevention of breast tumors development in vivo by downregulation of the p185neu receptor
22. A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors
23. Antibody-induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of c-erbB-2 (Her-2/neu) gene product p185
24. Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen
25. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo
26. Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: Evidence for receptor-enhanced chemosensitivity
27. Alloantigen-activated lymphocytes from mice bearing a spontaneous 'nonimmunogenic' adenocarcinoma inhibit its growth in vivo by recruiting host immune reactivity
28. Immune events associated with the cure of established tumors and spontaneous metastases by local and systemic IL-12
29. Antitumor efficacy of adenocarcinoma cells engineered to produce IL-12 or other cytokines compared with exogenous IL-12
30. Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies
31. Secretory IgA antibodies synergize with IgG in promoting ADCC by human polymorphonuclear cells, monocytes and lymphocytes
32. neu protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinoma
33. + lymphocyte driven and eosinophil-mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to release IL-4
34. Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory